Literature DB >> 16322368

Distribution and function of muscarinic receptor subtypes in the ovine submandibular gland.

G Tobin1, A T Ryberg, S Gentle, A V Edwards.   

Abstract

The effects of muscarinic receptor antagonists on responses to electrical stimulation of the chorda-lingual nerve were determined in pentobarbitone-anesthetized sheep and correlated to the morphology of tissue specimens. Stimulation at 2 Hz continuously, or in bursts of 1 s at 20 Hz every 10 s, for 10 min induced similar submandibular fluid responses (19 +/- 3 vs. 21 +/- 3 microl x min(-1) x g gland(-1)), whereas vasodilatation was greater during stimulation in bursts (-52 +/- 4 vs. -43 +/- 5%; P < 0.01). Continuous stimulation at 8 Hz induced substantially greater responses (66 +/- 9 microl x min(-1) x g gland(-1) and -77 +/- 3%). While atropine (0.5 mg/kg iv) abolished the secretory response at 2 and 20 Hz (1:10 s), a small response persisted at 8 Hz (<5%). The "M1-selective" antagonist pirenzepine (40 microg/kg iv) reduced the fluid response at all frequencies tested (P < 0.05-0.01), most conspicuously at 2 Hz (reduced by 69%). Methoctramine ("M2/M4-selective"; 100 microg/kg iv; n = 5) had no effect on fluid or the vascular responses but increased the protein output at 2 (+90%, P < 0.05) and 8 Hz (+45%, P < 0.05). The immunoblotting showed distinct bands for muscarinic M1, M3, M4, and M5 receptors, and immunohistochemistry showed muscarinic M1 and M3 receptors to occur in the parenchyma. Thus muscarinic M1 receptors contribute to the secretory response to parasympathetic stimulation but have little effect on the vasodilatation in the ovine submandibular gland. Increased transmitter release caused by blockade of neuronal inhibitory receptors of the M4 subtype would explain the increase in protein output.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322368     DOI: 10.1152/japplphysiol.00779.2005

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  8 in total

1.  Lack of specificity of commercially available antisera: better specifications needed.

Authors:  Wisuit Pradidarcheep; Wil T Labruyère; Noshir F Dabhoiwala; Wouter H Lamers
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

Review 2.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

Review 3.  Anticholinergic medication: Related dry mouth and effects on the salivary glands.

Authors:  Szilvia Arany; Dorota T Kopycka-Kedzierawski; Thomas V Caprio; Gene E Watson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2021-08-29

4.  Central muscarinic receptor subtypes involved in pilocarpine-induced salivation, hypertension and water intake.

Authors:  T L Borella; L A De Luca; D S A Colombari; J V Menani
Journal:  Br J Pharmacol       Date:  2008-09-29       Impact factor: 8.739

5.  Characterization of Prejunctional Muscarinic Receptors: Effects on the Release of VIP and Functional Responses and Receptor Expression in the Ovine Submandibular Gland.

Authors:  Anders T Ryberg; Ondrej Soukup; Gunnar Tobin
Journal:  Adv Pharmacol Sci       Date:  2009-05-25

6.  Intestinal epithelial stem/progenitor cells are controlled by mucosal afferent nerves.

Authors:  Ove Lundgren; Mats Jodal; Madeleine Jansson; Anders T Ryberg; Lennart Svensson
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

7.  Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2021-05-13       Impact factor: 2.705

Review 8.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.